Introduction
Experimental autoimmune encephalomyelitis (EAE), is an autoimmune disease of the central nervous system (CNS) which serves as a model for the human disease, multiple sclerosis (MS), since in both diseases circulating leukocytes penetrate the blood-brain barrier and damage myelin resulting in impaired nerve conduction and paralysis. 1, 2 We have previously used molecular biological techniques to follow leukocyte trafficking to the site of inflammation in the CNS of EAE rats, and suggested a model that characterizes this process as a sequential multi-step event in which a primary influx of T cells interact with its target antigen to activate the blood-brain barrier and initiate a secondary influx to commence the disease. 3 We have also developed various ways to inhibit the accumulation of the secondary influx at the target organ and thus block, or even reverse an ongoing disease. [4] [5] [6] [7] This includes adhesion molecule blockade, 4 T cell receptor antagonism, 5 and soluble peptide therapy using non-pathogenic tolerizing analogs of the encephalitogenic determinant. [5] [6] [7] Accumulation of the secondary influx at the site of inflammation is dependent on various pro-inflammatory cytokines and chemokines that are produced at the site of inflammation. [8] [9] [10] [11] Based on their cytokine profile, CD4
+ T cells can be divided into Th1 cells that produce large amounts of Correspondence: N Karin Received 4 November 1998; accepted 1 February 1999 interferon gamma (IFN-␥) and TNF-␣, and, to a much lesser extent, IL-4 and IL-10; Th2 cells that produce IL-4, IL-10 and IL-13 and, to a much lesser extent, IFN-␥ and TNF-␣. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Th1 cells selected in response to various autoantigens transfer T cell-mediated autoimmune diseases, whereas IL-4-secreting Th2 cells, selected in response to these same antigens, either inhibit or exert no profound effect on the inflammatory process. 16, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] High levels of IFN-␥ and low levels of IL-4 positively select for Th1 cells, whereas low levels of IFN-␥ together with high levels of IL-4 mediate Th2 selection. [12] [13] [14] [15] [16] [17] In a recent study, we isolated mRNA encoding interferon gamma-inducing factor (IGIF, IL-18) from the EAE brain, generated neutralizing antibodies against its gene product and explored the critical role of IGIF in T cell selection and regulation of disease. 35 The protective administration of IGIF-specific antibodies selects low IFN-␥, low TNF-␣, high IL-4-producing T cells. 35 While the role of IFN-␥ in the manifestation of EAE is enigmatic, the pivotal role of TNF-␣ has been well studied. TNF-␣ is produced by activated T cells (mostly Th1) and macrophages, and its elevated expression at the site of inflammation occurs during the critical phase of disease, 11 at the time when the 'secondary influx' of leukocytes is apparent. 3 Except for a single recent study carried out in genetically modified animals, 36 all investigators agree that TNF-␣ contributes to the pro-inflammatory process in EAE, and probably MS. 25, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Thus, inhibition of TNF-␣ activity by either neutralizing antibodies or soluble TNF receptor therapy, effectively prevents, or even reverses EAE. ease, 46 whereas genetically impaired expression of this gene inhibited the development and progression of disease. 43 Its pivotal role in T cell-mediated autoimmune diseases makes TNF-␣ a favorable target for clinical trials aiming at inhibiting MS and rheumatoid arthritis (RA). From a clinical perspective, a major disadvantage in treating these chronic diseases with xenogenic neutralizing antibodies, or even chimeric humanized antibodies (reviewed in Ref. 52 ), lies in their immunogenicity. Following repeated immunization, even these engineered antibodies do trigger an apparently allotypic response. We have recently utilized the novel technology of naked DNA vaccination [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] to generate self-specific protective immunity against C-C chemokines and inhibit EAE. 63 Resistance could be transferred by C-C chemokine-specific neutralizing antibodies. 63 The apparent advantage of this method of therapy motivated us to evaluate its therapeutic potential against TNF-␣.
Results
Levels of mRNA encoding TNF-␣ increase in the inflamed brain before onset and during disease progression Lewis rats immunized with guinea-pig myelin basic protein (MBP) emulsified in complete Freund's adjuvant (CFA) develop the active form of EAE. At the onset of disease, the immune T cell response is directed against a major encephalitogenic determinant comprising the residues 68-86 of the peptide and then to a secondary determinant encompassed by the residues 87-89 of this peptide. [64] [65] [66] We generated long-term CD4 + T cell lines in response to each of the above determinants. 3, 5 We named these lines according to their target determinant, L68-86 and L87-99. 3, 5 Each line is encephalitogenic, that is the line is capable of transferring EAE to naive recipients.
Rats injected with L68-86 developed transferred EAE that persisted for 5-6 days ( Figure 1a ). Before adoptive transfer of disease (day 0), and at various time-points (before the onset of disease (day 3), at the day of onset (day 5), the peak (day 7), following recovery (day 10), and 10 days after recovery (day 20) ) midbrain-brain stem samples were obtained from six different rats at each time-point. From each sample mRNA was isolated and subjected to RT-PCR analysis using specific oligonucleotide primers which we constructed. Each amplification was calibrated to ␤-actin and verified by Southern blotting analysis. This enabled semi-quantitative analysis of the levels of mRNA encoding TNF-␣ at the site of inflammation during different stages of the disease. Figure 1c shows representative results from each time-point of the experiment. mRNA encoding TNF-␣ was apparent in EAE brains at the onset of disease (day 5), peaked at the time when clinical disease attained its maximal severity (day 7), and gradually regressed following recovery. Markedly reduced but still notable levels of TNF-␣ mRNA in EAE brains could be observed even 10 days after recovery (Figure 1c) .
Rats with developing active disease (Figure 1b ) manifested a similar pattern of mRNA levels at the site of inflammation as those with developing transferred disease. That is, mRNA encoding TNF-␣ was apparent at the CNS just before the onset of disease (day 8) with substantial augmentation at the time when clinical disease attained its maximal severity (day 13), and marked regression following recovery (Figure 1d ).
Prevention of EAE using TNF-␣ naked DNA vaccines Cloned PCR products of rat TNF-␣, obtained as described above, were ligated into a pcDNA3 eukaryotic expression vector and used as constructs for naked DNA vaccination. Rats were subjected to 3 weekly injections of the above construct. Control rats were either injected with the pcDNA3 vector alone, or with PBS. Two months after the last immunization all rats were immunized with p68-86/CFA to induce active EAE. All control (PBSimmunized) and pcDNA3-vaccinated rats developed active disease that persisted for 5-6 days ( Figure 2 , six of six in each group with a maximum clinical score of 3 ± 0.28 in control, 2.83 ± 0.18 in pcDNA3-immunized rats). In contrast, rats injected with the TNF-␣-naked DNA vaccine were resistant to EAE (incidence of two of six with a maximum clinical score of 0.33 ± 0.2, P Ͻ 0.003 for treatment with TNF-␣-naked DNA vaccine compared with either control or pcDNA3 treatments). Thus, the subsequent in vivo immune response to TNF-␣-naked DNA vaccine augmented in rats during the development of EAE prevented the disease.
RT-PCR analyses of the levels of mRNA encoding TNF-␣ in the brain and spinal cord of naked DNA-vaccinated EAE-resistant rats (samples were obtained 12 days after active EAE induction) revealed a marked decrease (data not shown), which was probably due to the marked reduction in the pro-inflammatory process, which occurs in the CNS of control EAE rats.
Generation of natural immunity to TNF-␣ in EAE rats
The development of anti-self immunity to TNF-␣ in EAE rats was evaluated. Just before active induction of disease (day 0) and when EAE attained its maximum severity (day 13) blood samples were analyzed for the production of antibodies against TNF-␣. Rats with developing EAE displayed a significantly increased TNF-␣-specific antibody titer as compared with rats immunized in hind foot pads with CFA alone (Figure 3d versus b, log 2 Ab titer of 11 ± 0.85 versus 7 ± 0.66, P Ͻ 0.05). These results are remarkable since both groups exhibited an extensive local inflammatory process at the site of CFA immunization (hind foot pads), with enhanced levels of TNF-␣ mRNA (data not shown). Nevertheless, only rats with developing EAE manifested an apparent level of mRNA encoding TNF-␣ at the CNS that substantially increased at the time when clinical disease attained maximum severity ( Figure 1d ). In contrast, rats immunized with CFA alone did not exhibit notable levels of mRNA encoding TNF-␣ in the brain samples at any time-point (0, 8, 13 and 21 days after CFA administration, data not shown). Thus, only the elevated levels of TNF-␣ mRNA at the CNS enabled the triggering of an anti-self response against this pro-inflammatory cytokine. This response was, however, not sufficient to prevent the development of an autoimmune condition (six of six sick rats, Figure  2 ).
Naked DNA encoding TNF-␣ augments TNF-␣-specific protective immunity The development of anti-self protective immunity in DNA-vaccinated rats was evaluated. When active EAE attained its maximum severity (day 13), blood samples of representative rats from the experiment described in the legend to Figure 2 were analyzed for the production of antibodies against TNF-␣ (Figure 3d , e and h), and for the kinetics of antibody production ( Figure 4 ). The notable anti-self antibody titer against TNF-␣ produced in EAE rats without DNA vaccination (Figure 3d versus b, log 2 Ab titer of 11 ± 0.85 versus 7 ± 0, P Ͻ 0.05), which was not sufficient to prevent the development of disease, was profoundly augmented in naked DNA-vaccinated rats (Figure 3h versus d and e, log 2 Ab titer of 28 ± 1.88 in rats vaccinated with the TNF-␣ construct versus 11 ± 0.85 in EAE rats vaccinated with pcDNA3 alone and 8 ± 0.8 in control EAE rats, P Ͻ 0.0001, for the comparison of h with either d or e).
Figure 1 Levels of mRNA encoding TNF-␣ increase in the inflamed brain before the onset and during disease progression. (a) and (c) Rats were injected with 10 7 L68-86 cells to develop transferred EAE (a). Before adoptive transfer of disease (day 0), and at various time-points (before the onset of disease (day 3), at the day of onset (day 5), the peak (day 7), following recovery (day 10) and 10 days after recovery (day 20) ) mid-brain and brain stem samples from six different rats at each time-point were examined. mRNA was isolated from each sample and subjected to RT-PCR analysis using specific oligonucleotide primers constructed to TNF-␣. Each amplification was calibrated to ␤-actin and verified by Southern blotting analysis (e and f). (c) Shows a representative Southern blot analysis of each time point. (b) and (d) Rats were immunized with p68-86/CFA and developed active EAE (b). Before the induction of disease (day 0), and at various time-points (before the onset of disease (day 8), at the peak (day 13) and 5 days after recovery (day 21)) mid-brain and brain stem samples from six different rats at each time-point were obtained and subjected to RT-PCR as described above. (d) Shows a representative Southern blot analysis from each time-point.

Figure 2 Prevention of EAE using TNF-␣-naked DNA vaccines. Rats were immunized weekly with the cloned PCR products of TNF-␣ ligated into a pcDNA3 eukaryotic expression vector, or with the pcDNA3 vector alone, or with PBS. Two months after the last immunization all rats
At different time-points: 0, 8, 10, 13, 21 and 35 days after active EAE induction, the kinetics of anti-self TNF-␣ antibody production in blood sera (Figure 4a ) and spinal cord fluid (SCF) (Figure 4b ) was determined. TNF-␣-specific antibody titer profoundly increased within 8 days of MBP p68-86/CFA immunization (blood sera: log 2 Ab titer of 26 ± 1.88 on day 8 versus 7 ± 1 on day 0, P Ͻ 0.001; SCF: log 2 Ab titer of 15 ± 1.3 on day 8 versus 6 ± 1.1 on day 0, P Ͻ 0.001). The increase was simultaneous with the accelerated levels of TNF-␣ mRNA at the site of inflammation (Figure 1) . At this time a highly significant difference could be observed between the production of TNF-␣-specific antibody titer in TNF-␣ DNA-vaccinated rats that were immunized with p68-86/CFA and those immunized with CFA alone (blood sera: log 2 Ab titer of 26 ± 1.88 versus 13 ± 0.6, P Ͻ 0.001; SCF: log 2 Ab titer of 15 ± 1.33 versus 8 ± 0.5, P Ͻ 0.005). Thus, administration of naked DNA encoding TNF-␣ augments the generation of anti-self antibodies against a pro-inflammatory cytokine that is involved in the induction and progression of the autoimmune condition.
TNF-␣-specific antibodies generated in naked DNAvaccinated rats are neutralizing antibodies Since DNA vaccination can potentially elicit both cellular and humoral responses against products of a given construct, it is difficult to know which of these responses contributed more to the development of EAE resistance in TNF-␣ DNA-vaccinated rats. Twelve to 13 days after active induction of EAE, when production of anti-self antibodies in naked DNA vaccinated rats attained its maximal titer (Figure 4 ), antibodies were purified (IgG fraction, Protein-G purification) and evaluated for their in vitro competence to neutralize the cytotoxic effect of TNF-␣ ( Figure 5 ). It appears that IgG from TNF-␣ DNAvaccinated rats abolished the cytotoxic activity of TNF-␣ on U937 cytotoxic T cells (natural red uptake determined in OD at 570 nm of 0.174 ± 0.008 versus 0.075 ± 0.007 and 0.004 ± 0.006 in the presence of 100 g per well IgG from TNF-␣ DNA-vaccinated rats, normal IgG or PBS and 1000 pg/ml TNF-␣, with backgrounds of 0.168, 0.166 and 0.165, respectively, P Ͻ 0.001 for the comparison of the first group with each of the control groups). Thus, antibodies produced in naked DNA-vaccinated rats are neutralizing antibodies.
TNF-␣-specific neutralizing antibodies generated in naked DNA-vaccinated rats are capable of transferring EAE resistance The TNF-␣-specific neutralizing antibodies (previous section above) were then evaluated for their competence to transfer protection against active EAE ( Figure 6 ). Starting 4 days before the onset of active EAE, rats were challenged with the above antibodies (100 g daily, days 6-13), or with IgG from rats that were vaccinated with either pcDNA3-TNF-␣ construct, or with pcDNA3 alone. Repeated administration of antibodies from TNF-␣ DNAvaccinated rats provided substantial protection from disease progression (mean maximum score of 1 ± 0.2 in rats treated with purified antibodies from TNF-␣ DNA-vaccinated donors versus 2.66 ± 0.3 and 2.83 ± 0.816 in rats treated with purified antibodies from PBS-or pcDNA3-treated rats, P Ͻ 0.001 for each comparison). Anti-sera from rats that were previously administered with pcDNA3 vaccine alone and then subjected to active induction of EAE, and anti-sera from rats that were previously administered with pcDNA3-TNF-␣ vaccine and then subjected to active induction of EAE, both manifested a similar MBP-specific antibody titer (data not shown). Yet only TNF-␣ DNA-vaccinated rats exhibited a profound TNF-␣-specific antibody titer. Thus, it is plausible that these antibodies reinstated the resistant state following anti-sera transfer.
Taken together, our results show that administration of naked DNA encoding TNF-␣ augments the generation of anti-self antibodies, specific to this pro-inflammatory cytokine, that are capable of blocking the development of an experimental autoimmune disease of the CNS and thus providing a tool by which the immune system is encouraged to elicit anti-self protective immunity to restrain its own harmful reactivity when such a response is needed.
Discussion
In the process of negative selection in the thymus many, but not all, self-reactive T cells are eliminated. Autoreactive T cells that escape thymic selection can be identified in both healthy individuals and those suffering from self destructive autoimmune diseases. 67 In healthy individuals self-tolerance is maintained in part through mechanisms acting outside the thymus that keep these autoreactive lymphocytes under control. Anti-inflammatory cytokines such as TGF-␤, IL-10, IL-4 and IL-13 produced by antigen-specific regulatory T cells and macrophages are involved in restraining the activity of autoreactive T cells, and for keeping the tolerant state
Figure 6 TNF-␣-specific antibodies produced by DNA vaccination provide subsequent protection from severe EAE. Six groups of six rats each were immunized with p68-86/CFA to develop active EAE. Starting 4 days before the onset of disease, rats were challenged daily (i.v., days 6-13) with 100 g of each of TNF-␣-specific neutralizing antibodies (IgG fraction, Protein-G purification) purified from sera of rats that were previously vaccinated with TNF-␣-naked DNA vaccine, and were then subjected to active induction of EAE as described in the legend to Figure 2. Purified IgG fraction from rats that were, or were not vaccinated with pcDNA3 and then subjected to active induction of disease, as well as sera from control rats that were or were not subjected to active induction of EAE, were all used as controls. EAE was monitored daily by an observer blind to the treatment protocol. Results are shown as mean clinical score of six rats in each group
under control. 22, 23, [30] [31] [32] [68] [69] [70] [71] [72] The current study demonstrates, for the first time, the appearance of 'natural' antiself antibodies to a key pro-inflammatory cytokine, TNF-␣, during the development of a T cell-mediated autoimmune disease of the CNS. These antibodies developed in rats immunized with p68-86/CFA and not with the CFA alone (Figure 3 ), even though both groups exhibited an extensive local inflammatory process at the site of CFA immunization. They are neutralizing antibodies ( Figure  5 ) capable of transferring EAE resistance ( Figure 6 ). The biological significance of the association between the elevated levels of TNF-␣ mRNA at a privileged autoimmune site (CNS) and the enhancement in anti-self response against this pro-inflammatory cytokine is apparent. After all, an ideal immune system would be selected in evolution to centralize its destructive competence against invading microbes rather than against the self tissues it was designed to protect. [73] [74] [75] The underlying mechanism by which the immune system distinguishes a gene product transcribed at a privileged autoimmune site from the same gene product transcribed at a local site of inflammation is, however, elusive. A partial explanation has been previously suggested by Cyster and his colleagues 76 who demonstrated that peripheral clonal exclusion of self-reactive B cells occurs at germinal centers of lymph nodes that drain tissues lacking immune surveillance (ie immune privileged areas), where competition for follicular niches do not exclude self-reactive cells from the recirculating B cell repertoire. The 'natural' production of anti-self antibodies to TNF-␣ in EAE susceptible rats, while it may modulate the degree of disease, was however, not sufficient to prevent the development of an autoimmune condition (six of six sick rats, Figure 2 ).
An ideal method of treating a disease caused by a malfunction of the immune system in distinguishing self from foreign would be to encourage this system to elicit self-protective immunity and thus restrain its own harmful reactivity when such a response is needed. This task has been achieved in the current study using the novel technology of naked DNA vaccination. A current use of endogenous cytokine genes in immunization protocols is for the increase of the pro-inflammatory (Th1) immune response against infectious agents such as tuberculosis, HIV and allergens such as mite proteins. 60, [77] [78] [79] [80] [81] [82] This technology has also proved successful in eliciting immunity to self-antigens such as T cell receptor V genes and the shift towards a Th2 cell response. 62 In another recent study, transforming growth factor beta (TGF-␤) DNA vaccines were evaluated for their competence to inhibit the development of cell wall-induced arthritis. 83 TGF-␤ is a well known inhibitory modulator of the immune system. Thus, the administration of TGF-␤ prevented EAE, whereas TGF-␤-specific neutralizing antibodies aggravated expression of the disease. 84, 85 In contrast to its regulatory role in EAE, TGF-␤ has been found to be important for the manifestation of arthritis. Thus, TGF-␤-specific neutralizing antibodies suppressed, rather than enhanced, the development of cell wall-induced arthritis. 86 Along with these data, a TGF-␤-specific naked DNA vaccine has recently been found to be capable of suppressing this disease. 83 TGF-␤ DNA vaccines were also found to be beneficial in inhibiting the development of experimental colitis 87 and SLE. 88 Since DNA vaccines represent a novel means of expressing antigens in vivo for the generation of both humoral and cellular immune responses 55, 59, 89 it is difficult to know which of these responses contributed more to the development of EAE resistance in TNF-␣ DNA-vaccinated rats. The traditional implication of naked DNA vaccines with the augmentation of Th1 immunity 80, 81 makes data analysis even more complicated. Nevertheless, our data showing that self-specific neutralizing antibodies to TNF-␣ produced by naked DNA vaccination can provide subsequent protection from severe EAE (Figure 6 ) strongly implies their pivotal role in the prevention of EAE. The mechanism by which TNF-␣-specific naked DNA vaccines augment production of anti-self neutralizing antibodies is not yet fully elucidated. We do not exclude the possibility that naked DNA vaccination elicits the activation of selfreactive T cells that help production of autoreactive antibodies to TNF-␣ when this cytokine is profoundly transcribed at an autoimmune privileged area.
This provides a new perspective for understanding the role of T cell and B cell selection in induction and maintenance of tolerance to self. In the process of negative selection, self-reactive T cells die when they encounter selfantigen in the thymus. 90, 91 Similarly, self-specific pre-B cells either die or undergo receptor editing in the bone marrow. 92 It is believed that those cells escaping central tolerance are subjected to various mechanisms acting outside the thymus or the bone marrow to keep them under control. This type of control has been termed peripheral tolerance. T cell anergy, 69 active suppression, 31, [68] [69] [70] T cell deletion 93, 94 and generation of anti-idiotypic immunity 95 have been described as key mechanisms that contribute to the maintenance of peripheral tolerance. The current study suggests, for the first time, that self-specific T and B cells, capable of mounting self-specific immunity against pro-inflammatory mediators, escape central tolerance to provide the immune system with a powerful tool with which it keeps its dangerous anti-self activity under control and thus maintains tolerance to self in the periphery. Moreover, as microbes and self-components are constructed from similar 'building blocks' and as central selection manifests its own limitations, anti-self immunity cannot be avoided, but rather has to be restrained by peripheral mechanisms. Moreover, it could well be that a substantial increase in the competence of the immune system to effectively to limit its T and B cell repertoire would result in a constrained ability effectively to confront infectious diseases. The case of natural immunity to TNF-␣, evoked during the course of a T cell-mediated autoimmune disease, demonstrates how the immune system has evolved to benefit from its own limited competence effectively to select against self reactivity. From a clinical perspective, a major disadvantage in treating chronic diseases with xenogenic neutralizing antibodies lies in their immunogenicity. This has motivated investigators to develop chimeric humanized antibodies (reviewed in Ref. 52) , and monoclonal antibodies engineered with human Ig heavy and light chain yeast artificial chromosome (YAC). 96 However, following repeated immunization, these engineered antibodies do trigger an apparently allotypic response. The therapeutic strategy suggested by our study has an advantage over the above methods since it resulted in the generation of immunity to autologous antigen only during the course of disease at the time when mRNA levels encoding the pro-inflammatory cytokine are profoundly elicited at the site of inflammation (Figures 1, 2, 3 and 4) .
The possible effect of TNF-␣-naked DNA vaccination on the ability of an individual to confront infectious diseases has not yet been evaluated. Nevertheless, the observation that CFA immunization alone does not elicit TNF-␣-specific immunity in DNA-vaccinated rats (Figure 3 ) implies that elicitation of natural immunity following naked DNA vaccination is not induced if TNF-␣ is not transcribed at the autoimmune site (Figure 3 ). This gives TNF-␣-naked DNA vaccination an apparent advantage as a candidate for clinical trials.
Materials and methods
Rats
Female Lewis rats, approximately 6 weeks old, were purchased from Harlan (Jerusalem, Israel) and maintained under SPF conditions in our animal facility.
Peptide antigens
Myelin basic protein (MBP) p68-86, Y G S L P Q K S Q R S Q D E N P V, was synthesized on a MilliGen 9050 peptide synthesizer (Burlington, MA) by standard 9-fluorenylmethoxycarbonyl chemistry. Peptides were purified by high performance liquid chromatography. Structure was confirmed by amino acid analysis and mass spectroscopy. Only peptides that were greater than 95% pure were used in our study.
Immunizations and active disease induction Rats were immunized subcutaneously in the hind foot pads with 0.1 ml of MBP epitope 68-86 (p68-86) dissolved in PBS (1.5 mg/ml) and emulsified with an equal volume of CFA (incomplete Freund's adjuvant supplemented with 4 mg/ml heat-killed Mycobacterium tuberculosis H37Ra in oil (Difco Laboratories, Detroit, MI, USA). Rats were then monitored daily for clinical signs by an observer blind to the treatment protocol. EAE was scored as follows: 0, clinically normal; 1, flaccid tail; 2, hind limb paralysis; 3, hind limb and partial front limb paralysis; 4, hind limb and total front limb paralysis.
Induction of transferred EAE EAE was induced by immunizing Lewis rats (intraperitoneally) with 10 8 activated spleen cells from EAE donors obtained as follows: 9 days after induction of active EAE, splenic cells were cultured (12 × 10 6 /ml) at 37°C in humidified air containing 7.5% CO 2 for 2 days in stimulation medium containing Dulbecco's modified Eagle's medium (Gibco BRL Life Technology) supplemented with 2-mercaptoethanol (5 × 10 −5 m), l-glutamine (2 mm), sodium pyruvate (1 mm), penicillin (100 g/ml), streptomycin (100 g/ml), 1% syngeneic serum and 20-30 g/ml of the immunizing epitope. Then, cells were separated on a Ficoll gradient (Sigma, St Louis, MO, USA), resuspended in PBS and injected into naive recipients.
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis
RT-PCR analysis, verified by Southern blotting, was utilized on brain samples according to the protocol we described elsewhere with some modifications. 3 Rats were killed by CO 2 narcosis. Brain samples containing mainly the midbrain and brain stem were obtained after perfusion of the rat with 160-180 ml of ice-cold phosphate buffer saline (PBS) injected into the left ventricle following an incision in the right atrium. Each sample was homogenized. Total RNA was extracted using the Tri-Zol procedure (Gibco BRL Life Technologies) according to the manufacturer's protocol. mRNA was then isolated (kit No. 1741985; Boehringer Mannheim, Mannheim, Germany), and reverse transcribed into first-strand cDNA exactly described in detail elsewhere.
3 First-strand cDNA was then subjected to 35 cycles of PCR amplification using specific oligonucleotide primers which we designed based on the published sequence of rat TNF-␣ as follows:
Rat TNF-␣ sense: 5Ј-ATGAGCACAGAAAGCATGAT-3Ј Rat TNF-␣ antisense: 5Ј-TCACAG AGCAATGAC TCCAAA-3Ј.
All RNA samples were calibrated to ␤-actin:
Rat ␤-actin sense: 5Ј-CATCGTGGGCCGCTCTAGGCA-3Ј Rat ␤-actin antisense: 5Ј-CCGGCCAGCCAAGTCCA-GACG-3Ј
The cycle profile was denaturation at 95°C for 60 s, annealing at 55°C for 60 s, and elongation at 72°C for 60 s. Amplified products were subjected to electrophoresis, transferred on to nylon membranes (MagnaGraph nylon transfer membrane, msi, Westborough, MA, USA), fixed with ultraviolet light (120 mJ) and hybridized with 10 6 c.p.m./ml of ␣ 32 P-labeled DNA fragments encoding the full-length PCR product of the TNF-␣ and of ␤-actin (random priming; Amersham, Arlington Heights, IL). PCR products were used as probes only after each PCR product was cloned and its sequence was verified as described below.
Cloning and sequencing of PCR products Each of the amplified PCR products described above was cloned into a pUC57/T vector (T-cloning Kit No. K1212, MBI Fermentas, Vilnius, Lithuania) and transformed to E. coli according to the manufacturer's protocol. Each clone was then sequenced (Sequenase ver 2; USB, Cleveland, OH, USA) according to the manufacturer's protocol. PCR products were selected to be used as constructs for naked DNA vaccination only after cloning and sequence verification.
DNA vaccination
DNA vaccination was performed according to Waisman et al 62 with some modifications as recently described elsewhere. 63 Sequenced PCR products were transferred into a pcDNA3 vector (Invitrogen, San Diego, CA, USA). Largescale preparation of plasmid DNA was conducted using Mega prep (Qiagen, Chatsworth, CA, USA). Cardiotoxin (Sigma) was injected into the tibialis anterior muscle of 6 to 8-week-old female Lewis rats (10 m per leg). One week following injection rats were injected with 100 g DNA in PBS. Four to 5 days after the first immunization one rat from each group was killed and mRNA levels encoding the relevant cytokine were verified using RT-PCR on tibialis anterior muscle samples. Thereafter, naked DNA vaccines were administered three to five times with intervals of 6-7 days between each injection.
Purification of antibodies and determination of TNF-␣-specific antibody titer Antibodies from rat sera were purified (IgG fraction) using a High-Trap Protein G column (Pharmacia, Piscataway, NJ, USA) according to the manufacturer's protocol. Then, antibody titer to TNF-␣ was determined by a direct ELISA assay: ELISA plates (Nunc, Roskilde, Denmark) were coated with 50 ng per well recombinant rat TNF-␣ (Genzyme, Cambridge, MA, USA). Serum from DNA vaccinated rats was added in serial dilutions from 2 5 to 2 30 to wells that were, or were not, previously coated with TNF-␣. Calculation of each titer was done by comparing the OD measured in wells coated with TNF-␣ with those not coated with this cytokine. Goat anti-rat alkaline phosphatase-conjugated antibodies (Sigma) were used as a labeled antibody. P-nitrophenyl phosphate (p-NPP) (Sigma) was used as a soluble alkaline phosphatase substrate. Results of triplicate experiments were calculated as log 2 antibody titer ± s.e.
Determination of the neutralizing activity of TNF-␣ specific antibodies Determination of the neutralizing activity of TNF-␣-specific antibodies was carried out as described in detail elsewhere, 97 with the modification of using the U937 monocyte cell line (ATCC CRL-1593.2), at a concentration of 4 × 10 4 cells per well as a target cell for the assay.
Statistical analysis
Significance of differences in Figures 3, 4 and 5 was examined using Student's t test. A value of P Ͻ 0.05 was considered significant. Mann-Whitney sum of ranks test was used to evaluate significance of differences in mean of maximal clinical score (Figure 2) . A value of P Ͻ 0.05 was considered significant.
